TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04268381

Intervention type: OTHER
Intervention: Biochemical analysis
Description: aMMP-8 is measured by immunofluorometric assay (IFMA).

Intervention type: OTHER
Intervention: Biochemical analysis
Description: aMMP-8 is measured by immunofluorometric assay (IFMA).

Intervention type: OTHER
Intervention: Biochemical analysis
Description: aMMP-8 is measured by immunofluorometric assay (IFMA).
Study: NCT00357552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: Twice daily
Study: NCT00123422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing retraining
Description: exercise training with computerized training program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heliox
Description: exercise training with a helium oxygen combination

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: exercise training
Study: NCT01657019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Description: 50 or 70 mg administered orally, once a day for 52 weeks
Study: NCT03089281

Intervention type: DEVICE
Group type: OTHER
Intervention: CRT-D
Description: Commercially approved quadripolar Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices and future generations of BSC X4 CRT-D devices approved by the appropriate regulatory bodies will be included in the trial. All devices utilized in the study will include SmartDelay™ and must be capable of providing SmartDelay recommendations for both biventricular pacing (BiV) and Left Ventricular (LV) only pacing. All enrolled subjects with implanted BSC X4 CRT-D system and identified with an RV-LV delay of ≥70ms were 1:1 randomized. Randomization occurred in the electronic data capturing system.

Intervention type: DEVICE
Group type: OTHER
Intervention: CRT-D
Description: Commercially approved quadripolar Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices and future generations of BSC X4 CRT-D devices approved by the appropriate regulatory bodies will be included in the trial. All devices utilized in the study will include SmartDelay™ and must be capable of providing SmartDelay recommendations for both biventricular pacing (BiV) and Left Ventricular (LV) only pacing. All enrolled subjects with implanted BSC X4 CRT-D system and identified with an RV-LV delay of ≥70ms were 1:1 randomized. Randomization occurred in the electronic data capturing system.
Study: NCT00842296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF ablation (ClosureFAST)
Description: Segmental RF Ablation with the CLF catheter
Study: NCT00967837

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsatile Intravenous Insulin Therapy
Description: Diabetic pts that meet trial criteria referred by an endocrinologist are given Pulsatile intravenous insulin therapy on a weekly basis. Weekly orders for insulin dosage is based upon pt response to therapy monitored by RQ and insulin resistance.
Study: NCT02902146

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bougie

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Study: NCT02795403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draw of 150ml, twice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draw of 150ml, twice
Study: NCT02791503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: IRE is based on permeabilization of the cell membrane through electrical pulses leading to apoptosis. Theoretically, IRE only affects viable tumor tissue, leaving surrounding vital structures relatively intact. It is therefore considered to cause less morbidity than thermal ablative strategies.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic ablative radiotherapy (SABR)
Description: Stereotactic ablative radiotherapy (SABR) is a form of external beam radiation that has important advantages over conventional radiotherapy such as a more precise and greater biological dose delivery and hence less toxicity and presumably better outcome.
Study: NCT02282605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XF-73 nasal gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XF-73 nasal gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal gel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chlorhexidine gluconate 2% topical cloths

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 2% topical cloths

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 2% topical cloths
Study: NCT04581694

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TAVI without contrast
Description: TAVI without contrast
Study: NCT01852409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study: NCT05428657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EC Brain After-school Program
Description: * Computerized Eye-tracking Attention and Impulse Control Training~* Computerized Temporal Processing Training~* Education on Relaxation, Stress Management and Healthy Balanced Diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional intervention
Description: Conventional cognitive training on their language and learning capacities (e.g., learning adjectives, logical reasoning, composition, reading words and story) and attention ability
Study: NCT02461277

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fast-track protocol
Description: Preoperatory management, epidural anesthetic management, avoiding the need opioid in postoperatory analgesia and use of an standardized postoperatory management protocol to an early oral intake and early mobilization. At the postoperative recovery room, after extubation and fully awake, patients started physiotherapy exercises, as physical exercises of moving up upper and lower extremities accompanied by deep breathing exercises. After than, the patients standed up beside the bed and if there was no complications, patients performed ambulation. The physiotherapist aided the patients during all period.
Study: NCT03770767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting Aspart insulin Fiasp
Description: Randomization to treatment with insulin Fiasp

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control (insulin Novorapid)
Description: Randomization to standard treatment with insulin Novorapid
Study: NCT04235751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional Coaching
Description: 6 individualized professional coaching sessions via phone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional Coaching
Description: 6 individualized professional coaching sessions via phone
Study: NCT03766737

Intervention type: DEVICE
Group type: OTHER
Intervention: An intelligent visual acuity diagnostic system for children
Description: An artificial intelligence to make evaluation and of children's vision.
Study: NCT03163303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Status Project Intervention
Description: 90 days of Facebook messaging, weekly live sessions targeting tobacco use

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Status Project + Alcohol Intervention
Description: 90 days of Facebook messaging, weekly live sessions targeting tobacco use and alcohol use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: 14-day supply of nicotine patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: 14-day supply of nicotine patch
Study: NCT03519295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: MPDL3280A administered every 2 weeks at 800 mg for 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mDCF
Description: 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5-FU at 1200 mg/m2/day for 2 days) every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mDCF
Description: 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5-FU at 1200 mg/m2/day for 2 days) every 2 weeks
Study: NCT00808080

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMLCTL
Description: Ex-vivo expanded cytotoxic autologous AML-reactive T cells (CTL)
Study: NCT04207762

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-AmBF3-TATE PET/CT
Description: Blood pressure, heart rate, and oxygen saturation levels and EKG monitoring (vital signs) will be recorded prior to the injection and at three other stages of the scan visit. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine blood draw
Description: Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after \[18F\]AmBF3-TATE administration.
Study: NCT03746158

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Description: subjects will be assigned to consume one capsule of curcumin (330 mg of curcumin per capsule) three times a day (one capsule with each meal).
Study: NCT02345993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extra fine Formoterol/Beclomethasone
Description: standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40, 60 minutes
Study: NCT01474252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSI
Description: All medications are administered only one dose before intubation~Anesthetics:~Propofol 2-2.5 mg/kg Thiopental 3-5mg/kg Etomidate 1-2mg/kg~Neuromuscular blocking agents:~Succinylcholine 1-1.5mg/kg Rocuronium 0.9mg/kg~Opioid:~Fentanyl 1-2ug/kg
Study: NCT04470076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment: Afatinib, pemetrexed, gemcitabine, cisplatin, carboplatin
Description: ① Eligible patients with non-squamous cell lung cancer will receive pemetrexed 500mg/m2, IV on day 1 and cisplatin 75mg/m2 or carboplatin area under curve (AUC) =5, on day 1 of a 3-week schedule for 3 cycles.~② Eligible patients with squamous cell lung cancer will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 or carboplatin AUC =5 on day 1 of a 3-week schedule for 3 cycles .~③Patient will take afatinib at dosage of 30mg per day 48 hours after chemotherapy and will stop 24 hours before next cycle of chemotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Description: The patients who respond to neoadjuvant treatment (CR+PR) and the patients who do not respond to therapy but could still undergo surgery (SD and PD) will receive radical lung resection 3-4 weeks later after neoadjuvant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment:afatinib
Description: The CR, PR and SD patients who have been treated surgically will take afatinib at a dosage of 30mg per day for 2 year.
Study: NCT04493788

Intervention type: OTHER
Intervention: Blood test, ultrasound and egg retrieval
Description: Blood tests will be performed to determine free testosterone levels, anti-mullerian hormone (AMH) and lipid profile including fasting plasma glucose and insulin. Women from both PCOS and control groups will be minimally stimulated with gonadotrophins and cumulus-oocytes complexes (COCs) will be aspirated from small antral follicles (2-8mm) without any ovulation triggering. Specifically, administration of highly purified human menopausal gonadotropin (HP-hMG) will start on cycle Day 3 of the menstrual period or a withdrawal bleeding. A pelvic ultrasound scan will be performed in the morning of the last stimulation day to schedule the oocyte collection. Cumulus-oocyte complexes retrieved 42 hours after the last gonadotropin injection will be collected, washed, denuded and individually stored for further molecular characterization.

Intervention type: OTHER
Intervention: Blood test, ultrasound and egg retrieval
Description: Blood tests will be performed to determine free testosterone levels, anti-mullerian hormone (AMH) and lipid profile including fasting plasma glucose and insulin. Women from both PCOS and control groups will be minimally stimulated with gonadotrophins and cumulus-oocytes complexes (COCs) will be aspirated from small antral follicles (2-8mm) without any ovulation triggering. Specifically, administration of highly purified human menopausal gonadotropin (HP-hMG) will start on cycle Day 3 of the menstrual period or a withdrawal bleeding. A pelvic ultrasound scan will be performed in the morning of the last stimulation day to schedule the oocyte collection. Cumulus-oocyte complexes retrieved 42 hours after the last gonadotropin injection will be collected, washed, denuded and individually stored for further molecular characterization.
Study: NCT02724748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Educational intervention for staff members will encourage collaboration between patients, relatives and staff members. Skills, intellectual resources, motivation and encouragement among staff members to make changes on the unit will be supported. More detailed content of the intervention to be used in each unit will be tailored based on preparatory phase of the study and individual needs of the unit. The educational intervention will be carried out beside usual care.
Study: NCT03378271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simultanious CGM/FGM
Description: Patients will use both CGM and FGM and document their values as well as documenting a capillary blood glucose value.
Study: NCT02404025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag was provided as white round film-coated tablets containing 12.5 mg or 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit ATG
Description: Rabbit ATG, as an intravenous drip infusion, diluted by 500 mL of saline or 5% glucose injection was administered at a dose of 2.5 to 3.75 mg per kg per day as a slow intravenous infusion over 6 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA
Description: CsA as capsules, oral solution, or fine granule, was administered at a dose of 3 mg per kg twice a day.
Study: NCT00098813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies
Study: NCT02061371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Study: NCT01610778

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid phosphate
Study: NCT03743857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: AP ankle mobilization
Study: NCT03777748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental implants and stud attachments
Study: NCT01588392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short bouts of structured physical activity
Description: Short bouts of structured physical activity preschools will be asked to implement age-appropriate 10 minute structured physical activity routines within the classroom setting followed by 20 minutes of usual unstructured playtime activities. Intervention will be implemented for a total of 30 minutes during both morning and afternoon gross motor playtime 5 days/week for 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unstructured physical activity
Description: Unstructured physical activity intervention will consist of 30 minutes of supervised unstructured free playtime twice. intervention will be delivered during both morning and afternoon gross motor playtime for 5 days/week for 6 months.
Study: NCT01993121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Training
Description: All subjects will perform three months of supervised exercise training.
Study: NCT00001213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysteamine
Study: NCT00687375

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Inguinal Hernia Repair
Description: Laparoscopic Inguinal Hernia Repair using Transabdominal preperitoneal (TAPP) Approach

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Inguinal Hernia Repair
Description: Laparoscopic Inguinal Hernia Repair using totally extra peritoneal (TEP) Approach
Study: NCT03079843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposure to particulate matter with N 95 facemask
Description: 2 hours' / day exposure to particulate matter face mask worn during exposure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposure to particulate matter with N 95 facemask
Description: 2 hours' / day exposure to particulate matter face mask worn during exposure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposure to particulate matter with no face mask
Description: 2 hours'/ day exposure to particulate matter with no face mask

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposure to particulate matter with no face mask
Description: 2 hours'/ day exposure to particulate matter with no face mask
Study: NCT03925779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil sedation
Study: NCT02004041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLY-686

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01957306

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dr. Tagliaferri's Menopause Formula
Description: Administered as 2 grams PO BID
Study: NCT03623529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJPC-501 (angiotensin II)
Description: Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Arm
Study: NCT00792168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine (Effexor)
Description: venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
Study: NCT03085602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Therapy focused on explaining the physiological and psychological effects of nicotine. Training is focused on adherence to smoking instructions, physiological and psychological effects of nicotine, reviewing reasons for quitting, and coping with smoking urges. Smokers will be asked to begin smoking on a set schedule leading up to their quit day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Therapy that provides health education on the importance of healthy eating. Participants will be instructed to smoke as usual.
Study: NCT03105752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire of understanding
Description: The study involved 12 clinical trials conducted in the Clinical Research Center Paris Est. Twenty participants per trial were offered to answer the Qualité de Compréhension des Formulaires d'information et de consentement questionnaire (QCFic) at the inclusion visit after receiving the information by the investigator and signed or refused to sign the form of consent.~Participants filled out the questionnaire in an isolated location, with no possibility of re-reading the information contained in the consent form. The questionnaire was immediately retrieved.
Study: NCT03933085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Support System (MSS)
Description: A calendar/notetaking system focused on training a person with MCI to use a specific external memory compensatory strategy to complete relevant IADLs independently.
Study: NCT02779556

Intervention type: OTHER
Group type: OTHER
Intervention: ACP Living with Diabetes Guide
Description: American Colleges of Physicians (ACP) Living Well with Diabetes Guide

Intervention type: OTHER
Group type: OTHER
Intervention: ADA Living Well with Diabetes Workbook
Description: American Diabetes Association (ADA) Living Well with Diabetes Workbook